Net product revenue to BioMarin related to Aldurazyme was $14.4 million for the fourth quarter of 2008. This reflects a reduction in net product revenue from the royalty payable to BioMarin by Genzyme due to the timing of inventory transfers to Genzyme, which were less than units shipped to third party customers by Genzyme during the fourth quarter of 2008. Net product revenue to BioMarin related to Aldurazyme was $72.5 million for the year ended December 31, 2008, which included $12.4 million of net incremental product transfer revenue during 2008.
Beginning January 1, 2008, as a result of the restructuring of the joint venture with Genzyme, BioMarin receives a royalty of 39.5% to 50% of worldwide net sales. BioMarin recognizes a portion of this amount as product transfer revenue when product is released to Genzyme. This amount will eventually be credited against the calculated royalties earned when the product is sold by Genzyme to third parties.
Net product revenue from Kuvan (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), was $15.1 million for the fourth quarter of 2008 and $46.7 million for the year ended December 31, 2008.
Collaborative Agreement Revenues
Collaborative agreement revenues for the fourth quarter of 2008 were $31.5
million and included the $30 million milestone payment from Merck Serono for
Kuvan marketing approval in the E.U., compared to $17.5 million for the fourth
quarter of 2007 which included the $15 million milestone payment from Merck
Serono for the filing of the MAA for Kuvan. Colla
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2009 PR Newswire.
All rights reserved